Psychological and Pharmacological Treatments for Major Depressive Disorder

Major Depressive Disorder (MDD) is a leading cause of global disability, marked by persistent low mood, diminished interest in activities and impairments in social and occupational functioning. Treatment strategies fall broadly into psychological interventions and pharmacological approaches, each with distinct mechanisms and empirical support. Psychological therapies encompass structured, evidence‐based modalities such as cognitive behavioural therapy (CBT), which targets maladaptive thought patterns and behaviours; interpersonal psychotherapy (IPT), which addresses relationship difficulties as maintaining factors; behavioural activation, which encourages engagement in reinforcing activities; and emerging third-wave therapies, including mindfulness-based cognitive therapy. Pharmacological treatments aim to rectify monoaminergic imbalances and include selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase inhibitors, alongside rapidly acting agents such as ketamine and novel compounds that promote synaptic plasticity. Combination treatment, integrating psychotherapy with medication, often enhances remission rates and reduces relapse risk. Recent advances have also explored digital delivery platforms, precision medicine guided by clinical and biological markers, and interventions tailored to individual symptom profiles. Despite these advances, challenges remain in predicting treatment response, managing side effects and ensuring global access to high‐quality interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Psychological and Pharmacological Treatments for Major Depressive Disorder publication trend

The graph below shows the total number of articles in psychological and pharmacological treatments for major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Major Depressive Disorder (MDD): A psychiatric diagnosis characterised by prolonged low mood, anhedonia and significant functional impairment.

Cognitive Behavioural Therapy (CBT): A structured psychotherapy aiming to identify and modify negative thoughts and maladaptive behaviours.

Interpersonal Psychotherapy (IPT): A time-limited therapy focusing on interpersonal relationships and role transitions linked to depressive symptoms.

Antidepressant Medication: Pharmacological agents, including SSRIs, SNRIs and tricyclics, that modulate neurotransmitter systems to alleviate depression.

Individual Participant Data Meta-analysis (IPD-MA): A meta-analytic method that pools raw data from multiple trials to enhance statistical power and precision.

Symptom-Oriented Therapy (SOrT) Metric: A proposed framework combining individual symptom profiles with meta-analytic effect sizes to guide personalised treatment allocation.

References

1. Comparative efficacy of interpersonal psychotherapy and antidepressant medication for adult depression: a systematic review and individual participant data meta-analysis. Psychological Medicine (2024).
2. Baseline depression severity as moderator on depression outcomes in psychotherapy and pharmacotherapy. Journal of Affective Disorders (2023).
3. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry. BMC Medicine (2020).